Several treatments for neuroendocrine tumors have been validated or investigated in prospective clinical trials focusing on the anti-proliferative effect including somatostatin analogs (SSAs), multi-kinase inhibitors such as sunitinib, axitinib lenvatinib and pazopanib and the mammalian target of rapamycin inhibitor (mTOR), Everolimus [15,16]. This evidence concerns the gene MTOR and neuroendocrine neoplasm.